SOLIGENIX, INC. Total Long-Term Debt
SOLIGENIX, INC. (SNGX) had Total Long-Term Debt of $0 as of 2024-12-31, per its 10-K filed 2025-03-21.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2025-03-21
- 2024-12-31: Long-term Debt $0.00.
- 2023-12-31: Long-term Debt $1.01M.
- 2023-09-30: Long-term Debt $1.42M.
- 2023-06-30: Long-term Debt $2.09M.
| Period end | Long-term Debt |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-21 |
| 2023-12-31 | $1.01M 10-K · filed 2025-03-21 |
| 2023-09-30 | $1.42M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $2.09M 10-Q · filed 2023-08-21 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |